Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2010
03/04/2010US20100056600 11beta-hsd1 active compounds
03/04/2010US20100056571 Novel pyrazole compounds as transforming growth factor (tgf) inhibitors
03/04/2010US20100056564 Association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent
03/04/2010US20100056553 Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
03/04/2010US20100056548 Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
03/04/2010US20100056546 Sulfonylurea inhibitors of atp-sensitive potassium channels
03/04/2010US20100056545 Novel phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of t-type calcium ion channel containing the same as an active ingredient
03/04/2010US20100056536 Method of treating atrial fibrillation
03/04/2010US20100056531 Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
03/04/2010US20100056528 Sulfonamide derivatives with therapeutic indications
03/04/2010US20100056518 Cycloalkylamine substituted isoquinolone derivatives
03/04/2010US20100056506 Substituted 2-amino-fused heterocyclic compounds
03/04/2010US20100056505 Substituted Pyrazalones
03/04/2010US20100056497 Amide derivative
03/04/2010US20100056490 Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors
03/04/2010US20100056460 Combination of organic compounds
03/04/2010US20100056459 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
03/04/2010US20100056435 Depsipeptides and Their Therapeutic Use
03/04/2010US20100056426 Use of iron chelator for the treatment of myocardial infarction
03/04/2010US20100055696 DRG11-Responsive (DRAGON) Gene Family
03/04/2010US20100055206 Use of ribose in first response to acute myocardial infarction
03/04/2010US20100055190 Sterol-Containing Compositions
03/04/2010US20100055173 Release of statins in the intestine
03/04/2010US20100055147 Angiotensin (1-7) eluting stent
03/04/2010US20100055146 Cyclic angiotensin analogs
03/04/2010US20100055145 Stent coatings for reducing late stent thrombosis
03/04/2010US20100055110 congestive heart failure, coronary restenosis, myocardial infarction, myocardial dysfunction, stroke and atherosclerosis; time-release and sustained-release drugs
03/04/2010US20100055093 Pan-cell surface receptor-specific therapeutics
03/04/2010CA2735460A1 Novel anti-arrhythmia agent
03/04/2010CA2735361A1 Thienopyrimidines for pharmaceutical compositions
03/04/2010CA2734981A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative
03/04/2010CA2733661A1 1-(4-ureidobenzoyl)piperazine derivatives
03/03/2010EP2158206A1 Substituted furopyrimidines and use thereof
03/03/2010EP2081572B1 Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
03/03/2010EP1698622B1 Treatment for severe aphasia in chronic-stage cerebrovascular disorder
03/03/2010EP1505973B1 Combinations for treating multiple myeloma
03/03/2010EP1386908B1 Amine derivative with potassium channel regulatory function, its preparation and use
03/03/2010EP1286682B1 Methods and compositions for inhibiting immunoglobulin-mediated-reperfusion injury
03/03/2010EP1100801B1 Use of cysteine derivatives for preparing a medicine for treating pathologies resulting from the formation of heterotrimeric g protein
03/03/2010CN101659639A Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
03/02/2010US7671252 Fad4, Fad5, Fad5-2, and Fad6, novel fatty acid desaturase family members and uses thereof
03/02/2010US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents
03/02/2010US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
03/02/2010US7671074 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others; N-{amino-[pyridin-2-yl-methyl)-amino]-methylene}-4-methylbenzenesulfonamide
03/02/2010US7671071 Crystal structure; antihistamines; histamine H1-antagonists; side effect reduction; storage stability
03/02/2010US7671050 (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors
03/02/2010US7671036 Positively-charged peptide nucleic acid analogs with improved properties
03/02/2010US7670829 from a simple carbon source; includes 17 alpha -hydroxypregnenolone, cortisol, cortexolone, 17 alpha -hydroxyprogesterone, and derivatives; genetic engineering
03/02/2010US7670826 Belonging to subfamily of human immunoglobulin superfamily; isolated antibodies and nucleic acids; transformed host cells; modulating transendothelial migration of leukocytes; inflammation, tumors
03/02/2010US7670769 IL1RL-1 as a cardiovascular disease marker and therapeutic target
03/02/2010US7670632 Saponin mixtures and compounds isolated from Acacia victoriae; glycosides of acacic or oleanolic acid; control of cell apoptosis and cytotoxicity; antitumor, -carcinogenic, -inflammatory and -proliferative agents; atherosclerosis
03/02/2010US7670592 Polyvinyl alcohol microspheres, injectable solutions and therapeutic uses of the same
03/02/2010CA2373833C Medicinal compositions for preventing or treating viral myocarditis
03/02/2010CA2292836C Prostaglandin pharmaceutical compositions
02/2010
02/25/2010WO2010022240A1 Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators
02/25/2010WO2010021412A1 Therapeutic material for cerebral infarction, and method for regeneration of brain tissue
02/25/2010WO2010021129A1 Apoptosis inhibitor
02/25/2010WO2010020959A1 Resveratrol-containing composition for treating heart failure
02/25/2010WO2010020786A1 Organ protection
02/25/2010WO2010020762A1 1,5-diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists
02/25/2010WO2010020639A1 Arabinoxylans for modulating the barrier function of the intestinal surface
02/25/2010WO2010020600A1 Use of dabigatranetexilate for treating patients with pulmonary hypertension
02/25/2010WO2010020363A1 Substituted 5-aminopyrazoles and use thereof
02/25/2010WO2010020307A2 Indazole-5-carboxylic acid hydrazide derivatives
02/25/2010WO2010019995A1 The erg transcription factor modulation of vascular development
02/25/2010WO2009149795A3 Heterocyclic cyclopropyl-substituted fxr binding compounds
02/25/2010WO2009146218A8 Compounds including an anti-inflammatory pharmacore and methods of use
02/25/2010WO2009144550A3 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
02/25/2010WO2009142988A3 Chitin micro-particles as an adjuvant
02/25/2010WO2009140101A3 Imidazopyridine compounds useful as mmp-13 inhibitors
02/25/2010WO2009126923A3 Estrogenic extracts of anemarrhena asphodeloides bge from the liliaceae family and uses thereof
02/25/2010WO2009106752A3 Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereof and therapeutic application thereof
02/25/2010WO2009106751A3 Derivatives of n-heterocyclic-6-heterocyclic-imidazo[l,2- a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
02/25/2010WO2009106750A3 Derivatives of 6-heterocyclic-imidazo[l,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof
02/25/2010WO2009073616A3 Compositions comprising vascular and myocyte progenitor cells and methods of their use
02/25/2010WO2002068414A8 Analogs of thalidomide as potential angiogenesis inhibitors
02/25/2010US20100049273 Use of late passage mesenchymal stem cells (mscs) for treatment of cardiac rhythm disorders
02/25/2010US20100048712 Acyclic Sulfamide Derivatives
02/25/2010US20100048711 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
02/25/2010US20100048704 Pharmaceutical and nutraceutical products comprising vitamin k2
02/25/2010US20100048702 Prevention of neutrophil recruitment
02/25/2010US20100048698 Macrocyclic diterpenes for treating conditions associated with protein kinase c
02/25/2010US20100048694 Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
02/25/2010US20100048654 Use of valsartan or its metabolite to in hibit platelet aggregation
02/25/2010US20100048650 Two pore channels as a therapeutic target to protect against myocardial ischemia and as an adjuvant in cardiac surgery
02/25/2010US20100048648 Thiophene derivatives as S1P1/EDGE1 receptor agonists
02/25/2010US20100048639 Oxadiazole derivates as s1p1 receptor agonists
02/25/2010US20100048636 Aspartic Protease Inhibitors
02/25/2010US20100048631 Piperidine GPCR Agonists
02/25/2010US20100048626 Aryl Substituted Pyridines and the Use Thereof
02/25/2010US20100048622 Crystalline forms of a biphenyl compound
02/25/2010US20100048618 Derivatives of 8-epiblechnic Acid and their Effects on Down-Regulation of Endothelin (ETA) receptor mRNA
02/25/2010US20100048617 Compounds
02/25/2010US20100048600 such as trans-2-[3'-oxospiro [cyclohexane- 1,1'(3'H)-isobenzofuran]-4yl]-5-(2-pyridyl) imidazo[4,5-b]pyridine, exhibiting neuropeptide Y antagonistic effects, used for the treatment of cardiovascular, nervous system, metabolic, gastrointestinal, sexual and respiratory system disorders; pharmacokinetics
02/25/2010US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
02/25/2010US20100048574 NOVEL HETEROCYCLIC NF-kB INHIBITORS
02/25/2010US20100048564 Fused bicyclic heteroaryl derivative
02/25/2010US20100048560 Pyrazolo pyridine derivatives as nadph oxidase inhibitors
02/25/2010US20100048557 Triazolopyridine JAK Inhibitor Compounds and Methods
02/25/2010US20100048556 Quinoxaline derivatives